Age-dependent rise in early Hemoglobin (Hb) decline contributes to a higher frequency of anemia in elder patients treated with peginterferon alfa-2b (Peg2b)/Ribavirin (RBV) for ch…
G Teuber, S Mauss, D Hueppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthoeft, B Moeller, N Dikopoulos, J Brack, D Hartmann, M Bilzer · Zeitschrift für Gastroenterologie · 2012 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Treatment of chronic hepatitis C with peginterferon/RBV is frequently complicated by anemia. Age older than 50 years and female gender are factors that increase the risk of anemia. We here investigated how these factors influence the incidence and onset of anemia. Methods: Data of patients treated for G1 infection within the German Peg2b/RBV observational study were retrospectively analyzed. In this real-life cohort study G1 infection was treated with Peg2b 1.5µg/kg/wk+weight-based RBV (800–1200mg/day) for up to 48 wks at 285 sites. Patients who discontinued for non-response or for any other reasons were i…
